vinpocetine has been researched along with Cochlear Hearing Loss in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (16.67) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Alatorre-Miguel, E; Durand-Rivera, A; Gutiérrez-Farfán, I; Reyes-Legorreta, C; Solís-Olguín, M; Verduzco-Mendoza, A | 1 |
| Agafonov, BV; Dadasheva, MN; Shevtsova, NN | 1 |
| Afon'kin, VIu; Dobretsov, KG; Sipkin, AV | 1 |
| Dadasheva, BB; Fasenko, VP; Kalinina, MV; Maliavina, US; Maliev, BM; Ovchinnikov, IuM | 1 |
| Davydov, AV; Khandazhapova, IuA; Soldatenko, MV; Solodilov, VIu; Starokha, AV | 1 |
| Kosztyła-Hojna, B | 1 |
2 trial(s) available for vinpocetine and Cochlear Hearing Loss
| Article | Year |
|---|---|
Evaluation of vinpocetine as a therapy in patients with sensorineural hearing loss: A phase II, open-label, single-center study.
Topics: Adult; Aged; Audiometry, Evoked Response; Evoked Potentials, Auditory; Female; Hearing; Hearing Loss, Sensorineural; Humans; Longitudinal Studies; Male; Middle Aged; Otoacoustic Emissions, Spontaneous; Prospective Studies; Sodium Channel Blockers; Treatment Outcome; Vinca Alkaloids; Young Adult | 2021 |
[The new scheme of cavinton application to the treatment of chronic neurosensory loss of hearing].
Topics: Acoustic Impedance Tests; Administration, Oral; Adult; Aged; Calcium Channel Blockers; Chronic Disease; Dose-Response Relationship, Drug; Hearing; Hearing Loss, Sensorineural; Humans; Infusions, Intravenous; Middle Aged; Nootropic Agents; Treatment Outcome; Vinca Alkaloids | 2009 |
4 other study(ies) available for vinpocetine and Cochlear Hearing Loss
| Article | Year |
|---|---|
[The neurologists's view of the etiology and treatment of sensorineural hearing impairment].
Topics: Adult; Aged; Aged, 80 and over; Clinical Trials as Topic; Hearing Loss, Sensorineural; Humans; Middle Aged; Multicenter Studies as Topic; Neurology; Neuroprotective Agents; Severity of Illness Index; Treatment Outcome; Vinca Alkaloids | 2013 |
[Cavinton prevention of neurosensory hypoacousis in patients with different forms of tuberculosis].
Topics: Adolescent; Adult; Aged; Female; Hearing Loss, Sensorineural; Humans; Male; Middle Aged; Tuberculosis; Vasodilator Agents; Vinca Alkaloids | 2003 |
[Pharmacophysiotherapy in combined treatment of neurosensory hypoacusis in the presence of circulatory disorders in the vertebral arteries].
Topics: Adult; Auditory Threshold; Blood Flow Velocity; Calcium Channel Blockers; Combined Modality Therapy; Electrophoresis; Female; Hearing Loss, Sensorineural; Humans; Male; Middle Aged; Vertebral Artery; Vinca Alkaloids | 2007 |
[Effect of ethyl ether of apovincaminic acid (Cavinton) on the ototoxic action of sisomicin in guinea pigs].
Topics: Animals; Anticonvulsants; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Guinea Pigs; Hearing Loss, Sensorineural; Male; Organ of Corti; Sisomicin; Vinca Alkaloids | 1990 |